Generation of induced pluripotent stem cells from a young-onset Parkinson's disease patient carrying the compound heterozygous PLA2G6 p.D331Y/p.M358IfsX mutations

被引：3

作者：

Chiu, Ching-Chi ^{[1
,2
,3
]}

Wang, Hung-Li ^{[1
,4
,5
]}

Weng, Yi-Hsin ^{[6
,7
]}

Chen, Rou-Shayn ^{[6
,7
]}

Chen, Chiung-Mei ^{[6
,7
]}

Yeh, Tu-Hsueh ^{[1
,8
]}

Lu, Chin-Song ^{[1
,7
]}

Chen, Yu-Jie ^{[1
]}

Liu, Yu-Chuan ^{[9
]}

Huang, Ying-Zu ^{[1
,5
,7
,10
]}

Chang, Kuo-Hsuan ^{[6
,7
]}

机构：

[1] Chang Gung Mem Hosp Linkou, Neurosci Res Ctr, Taoyuan, Taiwan

[2] Chang Gung Univ, Coll Med, Dept Med Biotechnol & Lab Sci, Taoyuan, Taiwan

[3] Chang Gung Univ Sci & Technol, Dept Nursing, Taoyuan, Taiwan

[4] Chang Gung Univ, Dept Physiol & Pharmacol, Coll Med, Taoyuan, Taiwan

[5] Chang Gung Univ, Coll Med, Hlth Aging Res Ctr, Taoyuan, Taiwan

[6] Chang Gung Univ, Coll Med, Taoyuan, Taiwan

[7] Chang Gung Mem Hosp Linkou, Dept Neurol, Taoyuan, Taiwan

[8] Taipei Med Univ Hosp, Dept Neurol, Taipei, Taiwan

[9] Taiwan Landseed Hosp, Div Sports Med, Taoyuan, Taiwan

[10] Natl Cent Univ, Inst Cognit Neurosci, Taoyuan, Taiwan

来源：

STEM CELL RESEARCH | 2019年 / 40卷

关键词：

D O I：

10.1016/j.scr.2019.101552

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

Mutations in PLA2G6 gene cause PLA2G6-associated neurodegeneration, including recessive familial type 14 of Parkinson's disease (PARK14). Previously, we identified PARK14 patients with compound heterozygous c.991G > T/c.1077G > A (p.D331Y/p.M358IfsX) mutations. The c.1077G > A mutation led to a four base-pairs deletion and frameshift mutation (p.M358IfsX) of PLA2G6 mRNA. We established induced pluripotent stem cells (iPSCs) from peripheral blood mononuclear cells of a female patient with compound heterozygous c.991G > T/c.1077G > A (p.D331Y/ p.M358IfsX) mutations by using Sendai-virus delivery system. The iPSCs exhibited pluripotency and in vivo differentiation potential. The iPSCs can be used for studying the molecular pathogenic mechanism of PARK14.

引用

页数：5

共 38 条

[31] Generation of an induced pluripotent stem cell line (UCLi026-A) from a patient with ADCY5-related disease carrying the heterozygous variant c.1253G > A; (p. Arg418Gln)
Alhaque, Sharmin
Budinger, Dimitri
Garavaglia, Barbara
Zorzi, Giovanna
Barral, Serena
Kurian, Manju A.
STEM CELL RESEARCH, 2025, 84
[32] Derivation of induced pluripotent stem cell SHEHDNi002-A from a 68-year-old Chinese Han Parkinson's disease patient carrying LRRK2 and DNAJC6 mutations
Liu, Hui
Zhao, Zongbo
Zhao, Jun
Xu, Luran
Li, Jinshi
Zhang, Bei
STEM CELL RESEARCH, 2024, 75
[33] Generation of an induced pluripotent stem cell line (TRNDi030-A) from a patient with Farber disease carrying a homozygous p. Y36C (c. 107 A>G) mutation in ASAH1
Brooks, Brianna M.
Yeh, Charles D.
Beers, Jeanette
Liu, Chengyu
Cheng, Yu-Shan
Gorshkov, Kirill
Zou, Jizhong
Zheng, Wei
Chen, Catherine Z.
STEM CELL RESEARCH, 2021, 53
[34] Generation of an induced pluripotent stem cell line (SHCDNRi001-A) from a patient with X -linked Alport syndrome carrying a heterozygous p.G409S (c. 1225 G > A) mutation in the COL4A5 gene
Sun, Lei
Zhang, Jing
Kuang, Xin-yu
Kang, Yu-lin
Wu, Ying
Huang, Wen-yan
STEM CELL RESEARCH, 2020, 45
[35] Generation of two induced pluripotent stem cell lines and the corresponding isogenic controls from Parkinson's disease patients carrying the heterozygous mutations c.815G > A (p.R272Q) or c.1348C > T (p. R450C) in the RHOT1 gene encoding Miro1
Chemla, Axel
Arena, Giuseppe
Onal, Gizem
Walter, Jonas
Berenguer-Escuder, Clara
Grossmann, Dajana
Grunewald, Anne
Schwamborn, Jens C.
Kruger, Rejko
STEM CELL RESEARCH, 2023, 71
[36] Generation of an Induced Pluripotent Stem Cell Line, ICGi042-A, by Reprogramming Peripheral Blood Mononuclear Cells from a Parkinson’s Disease Patient with c.1000G>A Mutation in the LRRK2 Gene
E. V. Grigor’eva
S. V. Pavlova
A. A. Malakhova
S. P. Medvedev
J. M. Minina
Y. V. Vyatkin
E. A. Khabarova
J. A. Rzaev
L. V. Kovalenko
S. M. Zakian
Russian Journal of Developmental Biology, 2023, 54 : 80 - 87
[37] Generation of an Induced Pluripotent Stem Cell Line, ICGi042-A, by Reprogramming Peripheral Blood Mononuclear Cells from a Parkinson's Disease Patient with c.1000G>A Mutation in the LRRK2 Gene
Grigor'eva, E. V.
Pavlova, S. V.
Malakhova, A. A.
Medvedev, S. P.
Minina, J. M.
Vyatkin, Y. V.
Khabarova, E. A.
Rzaev, J. A.
Kovalenko, L. V.
Zakian, S. M.
RUSSIAN JOURNAL OF DEVELOPMENTAL BIOLOGY, 2023, 54 (01) : 80 - 87
[38] Generation of an induced pluripotent stem cell (iPSC) line (IGIBi026-A) derived from Wilson disease patient harboring compound heterozygous mutations [c.2165dupT (p.R723Efs31) and c.C813A (p.C271*)] in the ATP7B gene
Saikia, Bhaskar Jyoti
Bhardwaj, Juhi
Saini, Arti
Rajan, Roopa
Binukumar, B. K.
STEM CELL RESEARCH, 2024, 81

← 1 2 3 4 →